Evaluation of the AIVARIX in Detecting Signs C 1-2 Classes of CVD

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

433 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-12-01

Study Completion Date

2024-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a multicenter observational study, which is carried out in frame of routine clinical practice in Russia. The program will include patients suggestive to chronic venous diseases (CVDs) including but not limited to those with C1 and C2 classes by CEAP classification, who will be seeking professional phlebologists' consultation. Study conduction is scheduled in Russia in 2022-2023. The planned number of patients is 414

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radiographic and Intravascular (IVUS) Evaluation of Venous Morphology During CCSVI Treatment

NCT01593891

To Determine the Safety and Validity of Venous Angioplasty and Valvuloplasty in the Treatment of CCSVI. In Addition, it Will Allow Researchers to Sub-classify Valve Morphology in Relation +3 more

UNKNOWN

The Alvision™ Interventional Cardiology Diagnostic Catheter Post Market Clinical Follow-up (PMCF) Study.

NCT05908422

Coronary Artery Disease Coronary Disease Vascular Diseases

COMPLETED

IVUS Analysis for Coronary Obstruction in TAVI

NCT05164796

Coronary Artery Occlusion

UNKNOWN NA

Coronary Atherosclerosis Disease Early Identification and Risk Stratification by Noninvasive Imaging

NCT03518437

Coronary Artery Disease

UNKNOWN

Prospective Data Collection of IVMRI Cases

NCT00558441

Coronary Plaque Lipid Characterization

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main goal of this study is to describe the AIVARIX app accuracy in detecting C1 and C2 classes by CEAP classification of chronic venous disease (CVD) in patients who are consulted by phlebologists on symptoms and signs suggestive to CVD.

At single visit, investigating physicians (phlebologists) will be assessing and collecting parameters of interest which they should input in eCRF.

Following data will be collected at the visit: a signed consent form from a patient, demographic characteristics (age, sex), eligibility of a patient to the inclusion/ non-inclusion criteria, 1 (one) image of skin area of interest, conclusion on presence or absence of CVD or any other pathologic condition(s) made as a result of objective/ instrumental examination. In case there will be any information related to safety of a Servier drug provided, investigating physician will also collect the information and fill in the PV form (Appendix 1).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Venous Disease CVD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with CVD

20 patients per 1 center: patients with CVD C1 class 4 patients with CVD C2 class; 2 patients with CVD with classes other than C1-C2 (C4-C6); 8 patients with either C0s CVD or with skin pathologic conditions of lower extremities other than CVD;

to estimate Sensitivity and Specificity AIVARIX app in detecting C1 and C2 classes of CVD

Intervention Type OTHER

to estimate Sensitivity and Specificity of the AI-based AIVARIX app in detecting C1 and C2 classes of CVD in patients who are seeking for professional advice from a phlebologist regarding symptoms and signs suggestive to CVD.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

to estimate Sensitivity and Specificity AIVARIX app in detecting C1 and C2 classes of CVD

to estimate Sensitivity and Specificity of the AI-based AIVARIX app in detecting C1 and C2 classes of CVD in patients who are seeking for professional advice from a phlebologist regarding symptoms and signs suggestive to CVD.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age over 18 years
* Written informed consent is provided
* Symptoms and signs of CVD or any other skin pathologic condition (s) of lower extremities for which a patient seeks for phlebologist's consultation
* Ability to fulfil the technical requirements for smartphones/ images

Exclusion Criteria

* Patients with mental/ psychiatric disabilities who are not able to understand objectives of the study and therefore provide a signed consent to participate in the study.
* Patient's decision to withdraw his/her consent to participate in the study at any moment of the study conduction

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No